Assessment of the value of hyoscine butylbromide (Buscopan®) in optimising image quality for patients undergoing pelvic magnetic resonance imaging
| ISRCTN | ISRCTN56242729 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN56242729 |
| Secondary identifying numbers | N0063139427 |
- Submission date
- 30/09/2004
- Registration date
- 30/09/2004
- Last edited
- 05/04/2012
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr B Taylor
Scientific
Scientific
X-Ray Diagnostic
Christie Hospital NHS Trust
Wimslow Road
Withington
Manchester
M20 4BX
United Kingdom
Study information
| Study design | A cohort observation, randomised single-blinded trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Screening |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | |
| Study objectives | To determine whether intravenous hyoscine butylbromide (Buscopan®) results in a significant improvement in magnetic resonance (MR) image quality and improves diagnostic accuracy, thereby benefitting patients. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Magnetic resonance imaging (MRI) |
| Intervention | Before pelvic magnetic resonance imaging patient will received either intravenous hyoscine butylbromide or a placebo. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Hyoscine butylbromide (Buscopan®) |
| Primary outcome measure | Overall image quality and visualisation of individual pelvic structures and visualisation of tumours on MR images, both with and without Buscopan®. |
| Secondary outcome measures | Not provided at time of registration |
| Overall study start date | 20/01/2004 |
| Completion date | 31/12/2008 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | Not provided at time of registration |
| Key inclusion criteria | Patients undergoing pelvic magnetic resonance imaging. |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 20/01/2004 |
| Date of final enrolment | 31/12/2008 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
X-Ray Diagnostic
Manchester
M20 4BX
United Kingdom
M20 4BX
United Kingdom
Sponsor information
Department of Health
Government
Government
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
| Website | http://www.dh.gov.uk/Home/fs/en |
|---|
Funders
Funder type
Government
Christie Hospital NHS Trust (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/11/2007 | Yes | No |
